Baird Maintains an 'Outperform' on Human Genome Sciences (HGSI); Disappointed & Lowering Numbers, but Think Patience Will Be Rewarded
Tweet Send to a FriendGet Alerts HGSI Hot Sheet
Price: $14.24 --0%
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 24
Rating Summary:
5 Buy, 18 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 24
Trade HGSI Now!
Baird maintains an 'Outperform' on Human Genome Sciences (NASDAQ: HGSI) price target now $19.00.
Baird analyst says, "Remain buyers despite reducing Benlysta estimates and price target (now $19) substantially. A $1M Benlysta miss ($19M versus $20M) we can accept. However, more troubling are intermediate trends (decelerating monthly revenue) and longer-term guidance (delayed profitability), which conflict with our survey data which we still think correctly characterizes positive physician prescribing intentions. With numerous marketing initiatives to convert intent into action still on the come, we think investors will ultimately be rewarded here - just not as soon as hoped."
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $12.73 yesterday, with a 52 week range of $10.40-$30.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Baird analyst says, "Remain buyers despite reducing Benlysta estimates and price target (now $19) substantially. A $1M Benlysta miss ($19M versus $20M) we can accept. However, more troubling are intermediate trends (decelerating monthly revenue) and longer-term guidance (delayed profitability), which conflict with our survey data which we still think correctly characterizes positive physician prescribing intentions. With numerous marketing initiatives to convert intent into action still on the come, we think investors will ultimately be rewarded here - just not as soon as hoped."
For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.
Shares of Human Genome Sciences closed at $12.73 yesterday, with a 52 week range of $10.40-$30.15.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- Jefferies Raises Numbers on hhgregg (HGG), But Remains on Sidelines
- Microsoft (MSFT) Rally Not Over Says UBS; Raises PT to $40
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Robert W Baird
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
